 |
Early Intervention in a Patient With Parkinson's Disease CME/CE Author Information and Disclosures Release Date: June 25, 2008; Valid for credit through June 25, 2009 | Physicians - maximum of 1.5 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 1.5 nursing contact hours (1.0 contact hours are in the area of pharmacology);
Pharmacists - 1.5 ACPE continuing education credits for pharmacists (0.15 CEUs) | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME/CE Activity Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Identify the clinical features and diagnostic modalities that distinguish Parkinson's disease from other disorders
- Discuss the rationale for early intervention in patients with Parkinson's disease, including potential impact on patient functioning and
health-related quality of life
- Evaluate data from randomized clinical trials on pharmacologic interventions in patients with early Parkinson's disease
- Individualize treatment regimens to improve symptoms and minimize adverse events
Authors and Disclosures Robert A. Hauser, MD, MBA
Disclosure:
Robert A. Hauser, MD, MBA, has disclosed that he served as an advisor or consultant to Allergan Sales, LLC, Bayer Schering Pharma AG, Biovail Pharmaceuticals, Boehringer Ingelheim France, Cephalon Inc., CombinatoRx, Eisai Limited, Elan Pharmaceuticals, EMD Serono, Inc., Genzyme Corporation, GlaxoSmithKline, HealthCare Research and Consulting, Impax Laboratories Inc., Kyowa Pharmaceutical Inc., Merck KgaA, National Institutes of Health, Novartis Pharmaceuticals Corporation,
Ortho-McNeil Janssen Scientific Affairs, Pharmacia, Prestwick Pharmaceuticals, Inc., Schering Plough Research Institute, Schwarz Pharma, SmithKline Beecham, Solvay Pharmaceuticals, Teva Neuroscience, Valent Pharmaceuticals International, and Vernalis. He received grants and research support from Acadia, Berlex Labs, Biogen Idec, Boehringer Ingelheim France, Cephalon, Inc., Daiichi Asubio Pharmaceuticals, Inc., Eisai Medical Research, Inc., GlaxoSmithKline, Kyowa Pharmaceutical, Inc.,
Mentor Corporation, Merck KgaA, Merz Pharmaceuticals, National Institutes of Health, National Institute of Neurological Disorders Stroke, Ovation Pharmaceuticals, Parkinson's Institute, Schering Plough Research Institute, Skye Pharma, Inc., Solvay Pharmaceuticals, Teva Neuroscience, Vernalis, Vivometrics, Inc., and Wellness Pharmaceuticals. He has served on the speaker's bureau for Allergan Sales, LLC, Bertek Pharmaceuticals, Boehringer Ingelheim France, Centapharm, Inc.,
GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Schwarz Pharma, Scienta Healthcare Education, Teva Neuroscience, UCB Pharmaceuticals, Inc., United BioSource Corporation, and Vernalis. Stephanie Kushner, PhD
Disclosure: Stephanie Kushner, PhD, is a member of the professional editorial group at Medscape and has reported no financial relationships relevant to the development of CME activities.
Lynne K. Schneider, PhD
Disclosure: Lynne K. Schneider, PhD, has disclosed no relevant financial relationships. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
This Activity is sponsored by Medscape Continuing Education Provider Unit. Medscape is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
Awarded 1.5 contact hour(s) of continuing nursing education for RNs and APNs; 1.0 contact hours are in the area of pharmacology. Provider Number: 6FDKKC-PRV-05
Contact This Provider
|
|
 Medscape is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Medscape designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) (Universal Program Number 461-000-08-025-H01-P).
Contact This Provider
|
|
